858 — Extrawell Pharmaceutical Holdings Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapNeutral

Market Cap
HK$95.60m
Enterprise Value
HK$114.28m
Revenue
HK$72.58m

Annual income statement for Extrawell Pharmaceutical Holdings, fiscal year end - March 31st, HKD millions except per share, conversion factor applied.

	2019 March 31st	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	HKAS	HKAS	HKAS	HKAS	HKAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	89.2	77.6	78.8	73.9	72.6
Cost of Revenue
Gross Profit	49.6	42.9	42.6	37.6	31.1
Selling / General / Administrative Expenses
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	17.1	-20.4	184	-75.3	-77.8
Operating Profit	72.1	98	-106	149	150
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	63.4	85.5	-120	132	131
Provision for Income Taxes
Net Income After Taxes	63.3	85.6	-120	131	130
Minority Interest
Net Income Before Extraordinary Items
Net Income	64	83.3	-121	131	129
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	71.9	92.6	-121	144	145
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.022	0.028	-0.051	0.044	0.044